{"id":34043,"date":"2025-05-23T22:57:31","date_gmt":"2025-05-23T14:57:31","guid":{"rendered":"https:\/\/flcube.com\/?p=34043"},"modified":"2025-05-23T22:57:32","modified_gmt":"2025-05-23T14:57:32","slug":"ascentage-pharma-to-present-data-on-lisaftoclax-and-alrizomadlin-at-asco-2025","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=34043","title":{"rendered":"Ascentage Pharma to Present Data on Lisaftoclax and Alrizomadlin at ASCO 2025"},"content":{"rendered":"\n<p>China-based Ascentage Pharma (<a href=\"https:\/\/www.google.com\/finance\/quote\/AAPG:NASDAQ\">NASDAQ: AAPG<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/6855:HKG\">HKG: 6855<\/a>) will present the latest data from two ongoing investigational studies evaluating lisaftoclax in various blood cancers and alrizomadlin in solid tumors at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. These key drug candidates are part of Ascentage\u2019s apoptosis-targeted pipeline.<\/p>\n\n\n\n<p><strong>Lisaftoclax Study Updates<\/strong><br>Lisaftoclax, a novel Bcl-2 inhibitor for the treatment of various hematological malignancies, will have its Phase Ib\/II study results updated. The study evaluated the drug in patients with treatment-na\u00efve (TN) or prior venetoclax-exposed myeloid malignancies when combined with azacitidine (AZA). Results showed an overall response rate (ORR) of 64% in patients with TN-myelodysplastic syndromes (MDS)\/chronic myelomonocytic leukemia (CMML), with complete response (CR) and marrow CR achieved by 29% and 36% of patients, respectively. In patients with diseases refractory to venetoclax, the ORR was 17% in patients with acute myeloid leukemia (AML)\/mixed phenotype acute leukemia (MPAL) and 50% in patients with high-risk MDS.<\/p>\n\n\n\n<p><strong>Alrizomadlin Study Results<\/strong><br>APG-115, a MDM2-p53 inhibitor, will present results from a Phase II study with or without toripalimab in patients with advanced adenoid cystic carcinoma (ACC) or other solid tumors. Results showed an ORR of 22.2% and a disease control rate (DCR) of 100% in 9 patients with ACC. The DCR was 100% in all patients with malignant peripheral nerve sheath tumor (MPNST), all 5 of whom achieved stable disease (SD). The ORR was 16.7% and DCR was 66.7% in 6 patients with liposarcoma (LPS). The ORR was 14.3% and DCR was 53.6% in patients with MPNST. Overall adverse reactions were controllable, regardless of whether APG-115 was used as monotherapy or in combination therapy.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2025052300040_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025052300040_c.\"><\/object><a id=\"wp-block-file--media-32bec0bf-e5d4-48ae-a845-b6d792d13e87\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2025052300040_c.pdf\">2025052300040_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2025052300040_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-32bec0bf-e5d4-48ae-a845-b6d792d13e87\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) will present the latest data from two ongoing&#8230;<\/p>\n","protected":false},"author":1,"featured_media":34045,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[106,200,17,985,3273],"class_list":["post-34043","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-academic-conference","tag-ascentage-pharma","tag-clinical-trial-results","tag-hkg-6855","tag-nasdaq-aapg"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Ascentage Pharma to Present Data on Lisaftoclax and Alrizomadlin at ASCO 2025 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) will present the latest data from two ongoing investigational studies evaluating lisaftoclax in various blood cancers and alrizomadlin in solid tumors at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. These key drug candidates are part of Ascentage\u2019s apoptosis-targeted pipeline.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=34043\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ascentage Pharma to Present Data on Lisaftoclax and Alrizomadlin at ASCO 2025\" \/>\n<meta property=\"og:description\" content=\"China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) will present the latest data from two ongoing investigational studies evaluating lisaftoclax in various blood cancers and alrizomadlin in solid tumors at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. These key drug candidates are part of Ascentage\u2019s apoptosis-targeted pipeline.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=34043\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-23T14:57:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-23T14:57:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2303-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34043#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34043\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Ascentage Pharma to Present Data on Lisaftoclax and Alrizomadlin at ASCO 2025\",\"datePublished\":\"2025-05-23T14:57:31+00:00\",\"dateModified\":\"2025-05-23T14:57:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34043\"},\"wordCount\":275,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34043#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2303-1.webp\",\"keywords\":[\"Academic conference\",\"Ascentage Pharma\",\"Clinical trial results\",\"HKG: 6855\",\"NASDAQ: AAPG\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34043#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34043\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=34043\",\"name\":\"Ascentage Pharma to Present Data on Lisaftoclax and Alrizomadlin at ASCO 2025 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34043#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34043#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2303-1.webp\",\"datePublished\":\"2025-05-23T14:57:31+00:00\",\"dateModified\":\"2025-05-23T14:57:32+00:00\",\"description\":\"China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) will present the latest data from two ongoing investigational studies evaluating lisaftoclax in various blood cancers and alrizomadlin in solid tumors at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. These key drug candidates are part of Ascentage\u2019s apoptosis-targeted pipeline.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34043#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34043\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34043#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2303-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2303-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Ascentage Pharma to Present Data on Lisaftoclax and Alrizomadlin at ASCO 2025\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34043#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ascentage Pharma to Present Data on Lisaftoclax and Alrizomadlin at ASCO 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ascentage Pharma to Present Data on Lisaftoclax and Alrizomadlin at ASCO 2025 - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) will present the latest data from two ongoing investigational studies evaluating lisaftoclax in various blood cancers and alrizomadlin in solid tumors at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. These key drug candidates are part of Ascentage\u2019s apoptosis-targeted pipeline.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=34043","og_locale":"en_US","og_type":"article","og_title":"Ascentage Pharma to Present Data on Lisaftoclax and Alrizomadlin at ASCO 2025","og_description":"China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) will present the latest data from two ongoing investigational studies evaluating lisaftoclax in various blood cancers and alrizomadlin in solid tumors at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. These key drug candidates are part of Ascentage\u2019s apoptosis-targeted pipeline.","og_url":"https:\/\/flcube.com\/?p=34043","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-23T14:57:31+00:00","article_modified_time":"2025-05-23T14:57:32+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2303-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=34043#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=34043"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Ascentage Pharma to Present Data on Lisaftoclax and Alrizomadlin at ASCO 2025","datePublished":"2025-05-23T14:57:31+00:00","dateModified":"2025-05-23T14:57:32+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=34043"},"wordCount":275,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=34043#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2303-1.webp","keywords":["Academic conference","Ascentage Pharma","Clinical trial results","HKG: 6855","NASDAQ: AAPG"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=34043#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=34043","url":"https:\/\/flcube.com\/?p=34043","name":"Ascentage Pharma to Present Data on Lisaftoclax and Alrizomadlin at ASCO 2025 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=34043#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=34043#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2303-1.webp","datePublished":"2025-05-23T14:57:31+00:00","dateModified":"2025-05-23T14:57:32+00:00","description":"China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) will present the latest data from two ongoing investigational studies evaluating lisaftoclax in various blood cancers and alrizomadlin in solid tumors at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. These key drug candidates are part of Ascentage\u2019s apoptosis-targeted pipeline.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=34043#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=34043"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=34043#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2303-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2303-1.webp","width":1080,"height":608,"caption":"Ascentage Pharma to Present Data on Lisaftoclax and Alrizomadlin at ASCO 2025"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=34043#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Ascentage Pharma to Present Data on Lisaftoclax and Alrizomadlin at ASCO 2025"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2303-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34043","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34043"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34043\/revisions"}],"predecessor-version":[{"id":34046,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34043\/revisions\/34046"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/34045"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34043"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=34043"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=34043"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}